Statistische Methodenforschung

Die biometrische und epidemiologische Methodenforschung befasst sich mit der Entwicklung und Optimierung statistischer Planungs- und Auswertungsstrategien. Übergeordnetes Ziel ist es aus den Forschungsdaten einen möglichst hohen und gleichzeitig validen Informationsgewinn ziehen zu können.

Unsere statistischen Forschungsschwerpunkte sind:

Publikationen

2024

Diagnostic test accuracy in longitudinal study settings: theoretical approaches with use cases from clinical practice
Böhnke J, Zapf A, Kramer K, Weber P, Karch A, Rübsamen N
J CLIN EPIDEMIOL. 2024;169:111314.

Corrigendum to "The impact of inaccurate assumptions about antibody test accuracy on the parametrisation and results of infectious disease models of epidemics" [Epidemics 46 (2024) 100741]
Chaturvedi M, Köster D, Rübsamen N, Jaeger V, Zapf A, Karch A
EPIDEMICS-NETH. 2024;47:100766.

The impact of inaccurate assumptions about antibody test accuracy on the parametrisation and results of infectious disease models of epidemics
Chaturvedi M, Köster D, Rübsamen N, Jaeger V, Zapf A, Karch A
EPIDEMICS-NETH. 2024;46:100741.

Current developments of the estimand concept
Fierenz A, Zapf A
PHARM STAT. 2024 [Epub ahead of print].

A diagnostic phase III/IV seamless design to investigate the diagnostic accuracy and clinical effectiveness using the example of HEDOS and HEDOS II
Pepić A, Stark M, Friede T, Kopp-Schneider A, Calderazzo S, Reichert M, Wolf M, Wirth U, Schopf S, Zapf A
STAT METHODS MED RES. 2024;33(3):433-448.

Statistical inference for diagnostic test accuracy studies with multiple comparisons
Westphal M, Zapf A
STAT METHODS MED RES. 2024;33(4):669-680.

Regression Analyses and Their Particularities in Observational Studies—Part 32 of a Series on Evaluation of Scientific Publications
Zapf A, Wiessner C, König I
DTSCH ARZTEBL INT. 2024;121(4):128-134.

2023

Studienabschnitt „Vom Symptom zur Erkrankung“ – Schritte in ein integriertes Zahnmedizincurriculum
Lemke R, Mirzakhanian C, Sehner S, Bruhn N
BUNDESGESUNDHEITSBLA. 2023;66(12):1363–1371.

Systematic comparison of approaches to analyze clustered competing risks data
Schmitt S, Buchholz A, Ozga A
BMC MED RES METHODOL. 2023;23(1):86.

Missing values and inconclusive results in diagnostic studies - A scoping review of methods
Stahlmann K, Reitsma J, Zapf A
STAT METHODS MED RES. 2023;32(9):1842-1855.

Nutzenbewertung von Diagnostik – Umgang mit unvollständiger Evidenz
Zapf A
Z EVIDENZ FORTBILD Q. 2023;179:106-111.

Metaanalyse
Zapf A, Röver C
2023. Moderne Verfahren der Angewandten Statistik . Gertheiss , Schmid M, Spindler M (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer Spektrum, Berlin, Heidelberg, 1-33.

2022

A semiparametric approach for meta-analysis of diagnostic accuracy studies with multiple cut-offs
Frömke C, Kirstein M, Zapf A
RES SYNTH METHODS. 2022;13(5):612-621.

Convergence Behavior of Optimal Cut-Off Points Derived from Receiver Operating Characteristics Curve Analysis: A Simulation Study
Gerke O, Zapf A
MATHEMATICS-BASEL. 2022;10(22):.

Sample size recalculation based on the prevalence in a randomized test-treatment study
Hot A, Benda N, Bossuyt P, Gerke O, Vach W, Zapf A
BMC MED RES METHODOL. 2022;22(1):.

Weighted composite time to event endpoints with recurrent events: comparison of three analytical approaches
Ozga A, Rauch G
BMC MED RES METHODOL. 2022;22(1):.

Diagnostic accuracy of cerebrospinal fluid biomarkers for the differential diagnosis of sporadic Creutzfeldt-Jakob disease: a (network) meta-analysis
Rübsamen N, Pape S, Konigorski S, Zapf A, Rücker G, Karch A
EUR J NEUROL. 2022;29(5):1366-1376.

Blinded sample size re-estimation in a comparative diagnostic accuracy study
Stark M, Hesse M, Brannath W, Zapf A
BMC MED RES METHODOL. 2022;22(1):115.

A multiple testing framework for diagnostic accuracy studies with co-primary endpoints
Westphal M, Zapf A, Brannath W
STAT MED. 2022;41(5):891-909.

2021

Biomarker-Guided Risk Assessment for Acute Kidney Injury: Time for Clinical Implementation?
Albert C, Haase M, Albert A, Zapf A, Braun-Dullaeus R, Haase-Fielitz A
ANN LAB MED. 2021;41(1):1-15.

Statistical model building: Background "knowledge" based on inappropriate preselection causes misspecification
Hafermann L, Becher H, Herrmann C, Klein N, Heinze G, Rauch G
BMC MED RES METHODOL. 2021;21(1):196.

Randomized test-treatment studies with an outlook on adaptive designs
Hot A, Bossuyt P, Gerke O, Wahl S, Vach W, Zapf A
BMC MED RES METHODOL. 2021;21(1):110.

Studies for the Evaluation of Diagnostic Tests- Part 28 of a Series on Evaluation of Scientific Publications
Hoyer A, Zapf A
DTSCH ARZTEBL INT. 2021;118:555-560.

A potential for seamless designs in diagnostic research could be identified
Vach W, Bibiza E, Gerke O, Bossuyt P, Friede T, Zapf A
J CLIN EPIDEMIOL. 2021;129:51-59.

Meta-analysis of diagnostic accuracy studies with multiple thresholds: Comparison of different approaches
Zapf A, Albert C, Frömke C, Haase M, Hoyer A, Jones H, Rücker G
BIOMETRICAL J. 2021;63(4):699-711.

12. Einsatz von Audience Response Systemen in der Lehre: Didaktisches Konzept und konkrete Beispiele
Zapf A, Cevirme S
2021. Zeig mir Health Data Science!. Herrmann C, Berger D, Weiß P, Burkholder P, Rauch P, Kruppa D (Hrsg.). 1. Aufl. Berlin: Springer Spektrum, Berlin, Heidelberg, 143-159.

2020

Reevaluation of risk factors for time to subsequent events after first stroke occurrence using a new weighted all-cause effect measure
Ozga A, Rauch B, Palm F, Urbanek C, Grau A, Becher H, Rauch G
BMC PUBLIC HEALTH. 2020;20(1):817.

Sample size calculation and re-estimation based on the prevalence in a single-arm confirmatory diagnostic accuracy study
Stark M, Zapf A
STAT METHODS MED RES. 2020;29(10):2958–2971.

Blinded sample size reestimation for negative binomial regression with baseline adjustment
Zapf A, Asendorf T, Anten C, Mütze T, Friede T
STAT MED. 2020;39(14):1980-1998.

Why do you need a biostatistician?
Zapf A, Rauch G, Kieser M
BMC MED RES METHODOL. 2020;20(1):23.

Adaptive trial designs in diagnostic accuracy research
Zapf A, Stark M, Gerke O, Ehret C, Benda N, Bossuyt P, Deeks J, Reitsma J, Alonzo T, Friede T
STAT MED. 2020;39(5):591-601.

2019

Introducing a new estimator and test for the weighted all-cause hazard ratio
Ozga A, Rauch G
BMC MED RES METHODOL. 2019;19(1):118.

High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
Rossi A, Voigtländer M, Klose H, Schlüter H, Schön G, Loges S, Paolini M, Bokemeyer C, Reck M, Tarro G, Binder M
J ONCOL. 2019;2019:8970645.

What makes a biostatistician?
Zapf A, Huebner M, Rauch G, Kieser M
STAT MED. 2019;38(4):695-701.

2018

A systematic comparison of recurrent event models for application to composite endpoints
Ozga A, Kieser M, Rauch G
BMC MED RES METHODOL. 2018;18(1):2.

Appraising Heterogeneity
Zapf A
2018. Diagnostic Meta-Analysis . Biondi-Zoccai G (Hrsg.). 1. Aufl. Berlin: Springer International Publishing, 125-160.

2017

Investigation of the performance of trimmed estimators of life time distributions with censoring
Clarke B, Höller A, Müller C, Wamahiu K
AUST NZ J STAT. 2017;59(4):513-525.

Do we consent to rules of consent and confidentiality?
Wegscheider K, Friede T
BIOMETRICAL J. 2017;59(2):235-239.

Big Data Analytics
Wegscheider K, Koch-Gromus U
2017. Lehrbuch Versorgungsforschung Systematik - Methodik - Anwendung. Pfaff H, A.M. Neugebauer E, Glaeske G, Schrappe M (Hrsg.). 2.. Aufl. Schattauer, 134-139.

Doppelgänger lehren uns das Grundprinzip des statistischen Testens
Zapf A, Frömke C, Rosenberger A
2017. Zeig mir mehr Biostatistik . Vonthein R, Burkholder I, Muche R, Rauch G (Hrsg.). Berlin, Heidelberg: Springer Spektrum, Berlin, Heidelberg, 61-70.

2016

Teilhabeforschung: Bedeutung, Konzepte, Zielsetzung und Methoden
Brütt A, Buschmann-Steinhage R, Kirschning S, Wegscheider K
BUNDESGESUNDHEITSBLA. 2016;59(9):1068-74.

Safety data from randomized controlled trials: applying models for recurrent events.
Hengelbrock J, Gillhaus J, Kloss S, Leverkus F
PHARM STAT. 2016;15(4):315-323.

Partial verification bias and incorporation bias affected accuracy estimates of diagnostic studies for biomarkers that were part of an existing composite gold standard
Karch A, Koch A, Zapf A, Zerr I, Karch A
J CLIN EPIDEMIOL. 2016;78:73-82.

Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example
Winzer K, Buchholz A, Schumacher M, Sauerbrei W
PLOS ONE. 2016;11(3):e0149977.

Measuring inter-rater reliability for nominal data - which coefficients and confidence intervals are appropriate?
Zapf A, Castell S, Morawietz L, Karch A
BMC MED RES METHODOL. 2016;16:93.

Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer
zu Eulenburg C, Suling A, Neuser P, Reuss A, Canzler U, Fehm T, Luyten A, Hellriegel M, Woelber L, Mahner S
PLOS ONE. 2016;11(11):e0165705.

2015

Simulating recurrent event data with hazard functions defined on a total time scale
Jahn-Eimermacher A, Ingel K, Ozga A, Preussler S, Binder H
BMC MED RES METHODOL. 2015;15:16.

Nutzenbewertung aus Sicht der Versorgungsforschung und der Epidemiologie.
Wegscheider K, Drabik A, Bleich C, Schulz H
BUNDESGESUNDHEITSBLA. 2015;58(3):298-307.

Die Versorgungsforschung als möglicher Profiteur von Big Data
Wegscheider K, Koch-Gromus U
BUNDESGESUNDHEITSBLA. 2015;58(8):806-812.

A wild bootstrap approach for the selection of biomarkers in early diagnostic trials
Zapf A, Brunner E, Konietschke F
BMC MED RES METHODOL. 2015;15:43.

Nonparametric meta-analysis for diagnostic accuracy studies
Zapf A, Hoyer A, Kramer K, Kuss O
STAT MED. 2015;34(29):3831-3841.

2014

Nonparametric ROC analysis for diagnostic trials.
Brunner E, Zapf A
2014. Methods and Applications of Statistics in Clinical Trials, . Balakrishnan N (Hrsg.). June 2014. Aufl. Wiley, 483-495.

A measure for assessing functions of time-varying effects in survival analysis
Buchholz A, Sauerbrei W, Royston P
Open J Stat. 2014;4(11):977-998.

A modified Wald interval for the area under the ROC curve (AUC) in diagnostic case-control studies
Kottas M, Kuss O, Zapf A
BMC MED RES METHODOL. 2014;14:26.

Disease-Management-Programme - was wurde bisher erreicht?
Wegscheider K, Drabik A, Kaduszkiewicz H, Schäfer I, Bussche van den H
2014. Ergebnisverbesserung durch Qualitätsmanagement - Aktuelle Maßnahmen, Nachweise, Stand der Evaluierung. Jonitz G, Mansky T, Scriba P, Selbmann H (Hrsg.). 1. Aufl. Köln: Deutscher Ärzte-Verlag, 145-154.

2013

Difference of two dependent sensitivities and specificities: Comparison of various approaches
Wenzel D, Zapf A
BIOMETRICAL J. 2013;55(5):705-718.

Letzte Aktualisierung aus dem FIS: 14.10.2024 - 22:33 Uhr